newsfilter
← Earnings
Earnings Releases·

Vanda Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Total net product sales reached $69.8 million in Q3 2026, a 24% year-over-year increase and 38% quarter-over-quarter rise, while net loss narrowed to $22.6 million compared to $62.5 million in Q2 2026.
  • Full-year 2026 revenue guidance was updated to exceed $240 million, with management expecting further operating expense reductions as key Phase III and launch-preparation activities conclude.
  • The commercial launch of BYSANITM is scheduled for Q4 2026, and the BLA for QuimilzaTM for GPP remains under FDA review with a PDUFA target date of December 12, 2026.
  • Positive Phase III results were announced for NEREUS™ (GLP-1 vomiting prevention) and HETLIOZ™ (DSWPD), prompting plans to submit supplemental NDAs for both indications.
Company
VANDA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology